HRP20171775T1 - Molekule protutijela koje vežu trombin i njihova uporaba - Google Patents
Molekule protutijela koje vežu trombin i njihova uporaba Download PDFInfo
- Publication number
- HRP20171775T1 HRP20171775T1 HRP20171775TT HRP20171775T HRP20171775T1 HR P20171775 T1 HRP20171775 T1 HR P20171775T1 HR P20171775T T HRP20171775T T HR P20171775TT HR P20171775 T HRP20171775 T HR P20171775T HR P20171775 T1 HRP20171775 T1 HR P20171775T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody molecule
- molecule according
- seq
- amino acid
- antibody
- Prior art date
Links
- 108090000190 Thrombin Proteins 0.000 title claims 4
- 229960004072 thrombin Drugs 0.000 title claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010014523 Embolism and thrombosis Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (11)
1. Izolirana molekula protutijela koja se specifično veže na regiju exosite 1 trombina, naznačena time da molekula protutijela sadrži VH domenu koja sadrži HCDR1, HCDR2 i HCDR3 koje imaju odgovarajuće sekvence iz SEQ ID NO 3, 4 i 5, te VL domenu koja sadrži LCDR2 i LCDR3 koje imaju odgovarajuće sekvence iz SEQ ID NO 8 i 9, te LCDR1 koja ima sekvencu iz SEQ ID NO: 7 ili LCDR1 koja ima sekvencu iz SEQ ID: 7 u kojem je mjesto glikozilacije mutirano uvođenjem supstitucije na amino kiselinskom ostatku koji odgovara S30 u SEQ ID NO: 6.
2. Molekula protutijela prema zahtjevu 1 naznačena time da inhibira aktivnost trombina.
3. Molekula protutijela prema bilo kojem zahtjevu 1 ili zahtjevu 2, naznačena time da molekula protutijela sadrži VH domenu koja ima sekvencu amino kiseline iz SEQ ID NO: 2.
4. Molekula protutijela prema bilo kojem prethodnom zahtjevu, naznačena time da molekula protutijela sadrži VL domenu koja ima sekvencu amino kiseline iz SEQ ID NO: 6 ili sekvencu amino kiseline iz SEQ ID NO: 6 u kojem je mjesto glikozilacije mutirano uvođenjem supstitucije na amino kiselinskom ostatku koji odgovara S30.
5. Molekula protutijela prema bilo kojem prethodnom zahtjevu, naznačena time da je cjelokupno protutijelo.
6. Molekula protutijela prema zahtjevu 5, naznačena time da je IgA ili IgG.
7. Molekula protutijela prema bilo kojem prethodnom zahtjevu, naznačena time da je monoklonsko protutijelo.
8. Molekula protutijela prema bilo kojem od zahtjeva 1 do 4 naznačena time da je fragment protutijela.
9. Farmaceutski pripravak naznačen time da sadrži molekulu protutijela prema bilo kojem od zahtjeva 1 do 8 i farmaceutski prihvatljivo pomoćno sredstvo.
10. Molekula protutijela prema bilo kojem od zahtjeva 1 do 8 naznačena time da je za uporabu u postupku liječenja ljudskog ili životinjskog tijela.
11. Molekula protutijela prema bilo kojem od zahtjeva 1 do 8 naznačena time da je za uporabu u postupku liječenja stanja posredovanog trombinom koje se bira od tromboze i embolije.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1121513.4A GB201121513D0 (en) | 2011-12-14 | 2011-12-14 | Thrombin-binding antibody molecules and uses thereof |
PCT/GB2012/053140 WO2013088164A1 (en) | 2011-12-14 | 2012-12-14 | Thrombin-binding antibody molecules and uses thereof |
EP12806641.2A EP2791177B1 (en) | 2011-12-14 | 2012-12-14 | Thrombin-binding antibody molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171775T1 true HRP20171775T1 (hr) | 2017-12-29 |
Family
ID=45560465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171775TT HRP20171775T1 (hr) | 2011-12-14 | 2017-11-16 | Molekule protutijela koje vežu trombin i njihova uporaba |
Country Status (33)
Country | Link |
---|---|
US (5) | US9518129B2 (hr) |
EP (2) | EP3275903A1 (hr) |
JP (2) | JP6216954B2 (hr) |
KR (1) | KR102114506B1 (hr) |
CN (2) | CN104053673B (hr) |
AU (2) | AU2012351858B2 (hr) |
BR (1) | BR112014014605A2 (hr) |
CA (1) | CA2856656C (hr) |
CO (1) | CO7101192A2 (hr) |
CY (1) | CY1119599T1 (hr) |
DK (1) | DK2791177T3 (hr) |
ES (1) | ES2642718T3 (hr) |
GB (1) | GB201121513D0 (hr) |
HK (2) | HK1202564A1 (hr) |
HR (1) | HRP20171775T1 (hr) |
HU (1) | HUE034793T2 (hr) |
IL (1) | IL232797B (hr) |
LT (1) | LT2791177T (hr) |
ME (1) | ME02901B (hr) |
MX (1) | MX353281B (hr) |
MY (1) | MY170980A (hr) |
NO (1) | NO2791177T3 (hr) |
PE (2) | PE20141706A1 (hr) |
PH (1) | PH12014501169A1 (hr) |
PL (1) | PL2791177T3 (hr) |
PT (1) | PT2791177T (hr) |
RS (1) | RS56510B1 (hr) |
RU (2) | RU2017144629A (hr) |
SG (1) | SG11201402560WA (hr) |
SI (1) | SI2791177T1 (hr) |
UA (1) | UA116531C2 (hr) |
WO (1) | WO2013088164A1 (hr) |
ZA (1) | ZA201403836B (hr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201121513D0 (en) | 2011-12-14 | 2012-01-25 | Cambridge Entpr Ltd | Thrombin-binding antibody molecules and uses thereof |
US9518128B2 (en) | 2011-12-14 | 2016-12-13 | Janssen Pharmaceuticals, Inc. | Thrombin-binding antibody molecules |
GB201310948D0 (en) * | 2013-06-19 | 2013-07-31 | Cambridge Entpr Ltd | Screening methods |
GB201310949D0 (en) * | 2013-06-19 | 2013-07-31 | Cambridge Entpr Ltd | Binding Motif |
CN107043423B (zh) * | 2016-02-05 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 凝血酶抗体、其抗原结合片段及医药用途 |
US20190315886A1 (en) * | 2016-02-05 | 2019-10-17 | Jiangsu Hengrui Medicine Co., Ltd. | Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof |
WO2018081534A1 (en) * | 2016-10-28 | 2018-05-03 | President And Fellows Of Harvard College | Assay for exo-site binding molecules |
WO2019030706A1 (en) | 2017-08-10 | 2019-02-14 | Janssen Pharmaceutica Nv | ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY |
WO2019035055A1 (en) | 2017-08-16 | 2019-02-21 | Janssen Pharmaceutica Nv | ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS |
WO2020003077A1 (en) * | 2018-06-25 | 2020-01-02 | Janssen Pharmaceutica Nv | Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68908175T2 (de) * | 1988-05-27 | 1994-03-03 | Centocor Inc | Gefriergetrocknete formulierung für antikörperprodukte. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5196404B1 (en) | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
US5240913A (en) | 1989-08-18 | 1993-08-31 | Biogen, Inc. | Inhibitors of thrombin |
CA2082643A1 (en) | 1990-05-10 | 1991-11-11 | Jan H. Nuijens | Inhibitors of factor xii activation and applications thereof |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5443827A (en) * | 1993-05-03 | 1995-08-22 | President And Fellows Of Harvard College | Fibrin-targeted inhibitors of thrombin |
EP0738156A1 (en) * | 1993-12-27 | 1996-10-23 | Hamilton Civic Hospitals Research Development, Inc. | Methods and compositions for inhibiting thrombogenesis |
GB9613718D0 (en) | 1996-06-29 | 1996-08-28 | Thrombosis Res Inst | Thrombin inhibitors |
US5985833A (en) | 1996-09-17 | 1999-11-16 | Wisconsin Alumni Research Foundation | Thrombin inhibitor |
WO2001000667A2 (en) | 1999-06-29 | 2001-01-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-thrombin peptide from anopheles albimanus salivary gland |
WO2001007072A1 (en) | 1999-07-23 | 2001-02-01 | The Regents Of The University Of California | Modulation of platelet activation |
EP1282444B1 (en) * | 2000-05-15 | 2006-11-22 | SmithKline Beecham Corporation | Antithrombotic agents |
WO2002017711A2 (en) | 2000-08-31 | 2002-03-07 | Cor Therapeutics, Inc. | Therapeutics and diagnostics based on a novel signal transduction system in platelets |
EP1411964A4 (en) * | 2001-07-06 | 2006-06-14 | Oregon Health Science Universi | THE BLOOD GENERATING PEPTIDES AND THEIR USES |
TWI338009B (en) * | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
ME00016B (me) | 2005-08-26 | 2010-06-10 | Aptameri koji vezuje trombin sa visokim afininitetom | |
WO2007106893A2 (en) | 2006-03-15 | 2007-09-20 | Emory University | Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors |
GB0711779D0 (en) | 2007-06-18 | 2007-07-25 | Univ Singapore | Thrombin inhibitor |
TR201820051T4 (tr) | 2008-06-19 | 2019-01-21 | Prothix Bv | Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması |
US20110275701A1 (en) * | 2008-09-18 | 2011-11-10 | Archemix Corp. | Anti-thrombin aptamer formulations and methods for use |
KR102042982B1 (ko) | 2011-07-22 | 2019-11-11 | 체에스엘 베링 게엠베하 | 억제성 항-xii/xiia 인자 모노클로날 항체 및 이들의 사용 |
GB201121513D0 (en) | 2011-12-14 | 2012-01-25 | Cambridge Entpr Ltd | Thrombin-binding antibody molecules and uses thereof |
US9518128B2 (en) | 2011-12-14 | 2016-12-13 | Janssen Pharmaceuticals, Inc. | Thrombin-binding antibody molecules |
-
2011
- 2011-12-14 GB GBGB1121513.4A patent/GB201121513D0/en not_active Ceased
-
2012
- 2012-12-14 NO NO12806641A patent/NO2791177T3/no unknown
- 2012-12-14 SG SG11201402560WA patent/SG11201402560WA/en unknown
- 2012-12-14 DK DK12806641.2T patent/DK2791177T3/en active
- 2012-12-14 SI SI201231145T patent/SI2791177T1/en unknown
- 2012-12-14 MY MYPI2014001764A patent/MY170980A/en unknown
- 2012-12-14 MX MX2014007170A patent/MX353281B/es active IP Right Grant
- 2012-12-14 CA CA2856656A patent/CA2856656C/en active Active
- 2012-12-14 RS RS20171073A patent/RS56510B1/sr unknown
- 2012-12-14 UA UAA201406892A patent/UA116531C2/uk unknown
- 2012-12-14 PL PL12806641T patent/PL2791177T3/pl unknown
- 2012-12-14 AU AU2012351858A patent/AU2012351858B2/en not_active Ceased
- 2012-12-14 CN CN201280061294.8A patent/CN104053673B/zh not_active Expired - Fee Related
- 2012-12-14 JP JP2014546649A patent/JP6216954B2/ja not_active Expired - Fee Related
- 2012-12-14 RU RU2017144629A patent/RU2017144629A/ru unknown
- 2012-12-14 ES ES12806641.2T patent/ES2642718T3/es active Active
- 2012-12-14 HU HUE12806641A patent/HUE034793T2/en unknown
- 2012-12-14 ME MEP-2017-243A patent/ME02901B/me unknown
- 2012-12-14 KR KR1020147019168A patent/KR102114506B1/ko active IP Right Grant
- 2012-12-14 WO PCT/GB2012/053140 patent/WO2013088164A1/en active Application Filing
- 2012-12-14 CN CN201711384542.3A patent/CN107936119B/zh not_active Expired - Fee Related
- 2012-12-14 RU RU2014124985A patent/RU2642276C2/ru active
- 2012-12-14 LT LTEP12806641.2T patent/LT2791177T/lt unknown
- 2012-12-14 EP EP17177235.3A patent/EP3275903A1/en not_active Withdrawn
- 2012-12-14 PE PE2014000953A patent/PE20141706A1/es active IP Right Grant
- 2012-12-14 US US14/363,514 patent/US9518129B2/en active Active
- 2012-12-14 PT PT128066412T patent/PT2791177T/pt unknown
- 2012-12-14 BR BR112014014605A patent/BR112014014605A2/pt not_active Application Discontinuation
- 2012-12-14 PE PE2018002007A patent/PE20190171A1/es unknown
- 2012-12-14 EP EP12806641.2A patent/EP2791177B1/en active Active
-
2014
- 2014-05-26 ZA ZA2014/03836A patent/ZA201403836B/en unknown
- 2014-05-26 PH PH12014501169A patent/PH12014501169A1/en unknown
- 2014-05-26 IL IL232797A patent/IL232797B/en active IP Right Grant
- 2014-07-11 CO CO14150372A patent/CO7101192A2/es unknown
-
2015
- 2015-03-27 HK HK15103146.0A patent/HK1202564A1/xx not_active IP Right Cessation
-
2016
- 2016-11-10 US US15/348,250 patent/US9988463B2/en active Active
-
2017
- 2017-08-30 JP JP2017165700A patent/JP6705785B2/ja not_active Expired - Fee Related
- 2017-11-14 CY CY20171101189T patent/CY1119599T1/el unknown
- 2017-11-16 HR HRP20171775TT patent/HRP20171775T1/hr unknown
- 2017-12-01 AU AU2017268655A patent/AU2017268655B2/en not_active Ceased
-
2018
- 2018-05-08 HK HK18105913.3A patent/HK1246326A1/zh unknown
- 2018-05-10 US US15/976,512 patent/US10287363B2/en not_active Expired - Fee Related
-
2019
- 2019-03-25 US US16/363,396 patent/US20190276558A1/en not_active Abandoned
-
2021
- 2021-06-10 US US17/344,577 patent/US20210371543A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171775T1 (hr) | Molekule protutijela koje vežu trombin i njihova uporaba | |
ES2732552T3 (es) | Anticuerpos neutralizantes del virus de la influenza A y usos de los mismos | |
HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
JP2020500538A5 (hr) | ||
NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
HRP20171992T1 (hr) | Protutijela protiv cgrp | |
SI3042917T1 (en) | PROTITELES AGAINST N3PGL AMILOID BETA PEPTID AND THEIR APPLICATION | |
HRP20201432T1 (hr) | Il-17a sredstvo za vezivanje i njegove uporabe | |
JP2013121353A5 (hr) | ||
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
JP2018521691A5 (hr) | ||
HRP20180776T1 (hr) | Antagonisti il17c za liječenje upalnih poremećaja | |
RU2668802C2 (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
JP2010523541A5 (hr) | ||
PE20081503A1 (es) | Miembros de union para il-6 | |
HRP20171964T1 (hr) | Kombinacije i njihova upotreba | |
JP2016538876A5 (hr) | ||
JP2015501830A5 (hr) | ||
JP2015522252A5 (hr) | ||
AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
RU2018110064A (ru) | Антитела к бета-амилоиду | |
HRP20161587T1 (hr) | Protutijela protiv bmp-6 | |
AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met |